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Abstract
Despite enzyme replacement therapy, disease progression is observed in patients with
Fabry disease. Identification of factors that predict disease progression is needed to refine
guidelines on initiation and cessation of enzyme replacement therapy. To study the associa-
tion of potential biochemical and clinical prognostic factors with the disease course (clinical
events, progression of cardiac and renal disease) we retrospectively evaluated 293 treated
patients from three international centers of excellence. As expected, age, sex and pheno-
type were important predictors of event rate. Clinical events before enzyme replacement
therapy, cardiac mass and eGFR at baseline predicted an increased event rate. eGFR was
the most important predictor: hazard ratios increased from 2 at eGFR <90 ml/min/1.73m2 to
4 at eGFR <30, compared to patients with an eGFR >90. In addition, men with classical dis-
ease and a baseline eGFR <60 ml/min/1.73m2 had a faster yearly decline (-2.0 ml/min/
1.73m2) than those with a baseline eGFR of >60. Proteinuria was a further independent risk
factor for decline in eGFR. Increased cardiac mass at baseline was associated with the
most robust decrease in cardiac mass during treatment, while presence of cardiac fibrosis
predicted a stronger increase in cardiac mass (3.36 gram/m2/year). Of other cardiovascular
risk factors, hypertension significantly predicted the risk for clinical events. In conclusion,
besides increasing age, male sex and classical phenotype, faster disease progression while
on enzyme replacement therapy is predicted by renal function, proteinuria and to a lesser
extent cardiac fibrosis and hypertension.
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Introduction
Fabry disease (FD, OMIM 301500) is a rare X-linked lysosomal storage disorder caused by
deficiency of the lysosomal enzyme alpha galactosidase A (aGAL, enzyme commission num-
ber: 3.2.1.22) due to mutations in the GLA gene (Xq22.1). Accumulation of glycosphingolipids,
particularly globotriaosylceramide (Gb3), in various cell types results in multi-system disease
[1, 2]. Long term disease manifestations include progressive renal failure, hypertrophic cardio-
myopathy, cardiac rhythm disturbances and stroke [3]. As a result, life expectancy is signifi-
cantly reduced, most clearly in untreated men with classical FD [4]. Classical disease in men is
characterized by multi-organ involvement, absent to very low aGAL activity and the presence
of specific FD symptoms including cornea verticillata, angiokeratoma and neuropathic pain
[5]. Non-classical men and women generally have a more attenuated disease course [6–8].
For the treatment of FD two recombinant enzyme preparations have been authorized in
Europe: agalsidase alfa (Replagal, Shire) and agalsidase beta (Fabrazyme, Sanofi Genzyme). In
the United States only agalsidase beta has been approved. Although treatment with enzyme
replacement therapy (ERT) reduces the accumulation of Gb3 and leads to a reduction of the
substrate biomarker globotriaosylsphingosine (lysoGb3) [9–11], the long term effectiveness is
variable [12, 13]. Several disease related factors have been shown to influence the risk for new
complications and progression of cardiac and renal failure. Severely impaired renal function at
the start of treatment, proteinuria and cardiac fibrosis have all been associated with ongoing
disease progression in patients receiving ERT [13–15]. In line with these findings it has been
hypothesized that initiation of treatment before the occurrence of irreversible damage might
lead to better outcomes [16, 17]. In addition, differences in disease phenotype and gender will
most likely also influence the risk for further complications, since the natural disease course in
these groups is different [5]. The exact influence of these disease characteristics is, however,
not known. Furthermore, common cardiovascular risk factors, and use of antiproteinuric,
antihypertensive and antiplatelet therapy may also impact the outcome. Ideally, the influence
of individual or combined clinical and biochemical characteristics on development of disease
progression or complications should be better understoord to improve and ensure appropriate
use of burdensome and costly ERT. In addition, a more comprehensive understanding of clini-
cal and biochemical characteristics underlying the outcome of FD patients might be used to
update existing guidelines on initiation and cessation of ERT [18, 19]. The currently available
large registries (i.e. Fabry Outcome Survey and Fabry Registry have, unfortunately, limited
complete datasets to address this issue [20]. Therefore, a multicenter database was created with
the aim to address the natural disease course and effects of ERT in FD patients. The current
study describes the influence of disease characteristics, comorbidities, medication use and
other cardiovascular risk factors on the risk to develop disease progression in patients with
FD.
Methods
Patients
This investigation is part of the multicenter retrospective cohort study on Fabry disease sup-
ported by the Dutch Government to establish appropriate use of enzyme replacement therapy
[21]. In brief, retrospective data from three European FD centers of excellence (Academic
Medical Center, The Netherlands; Royal Free London NHS Foundation Trust, United King-
dom; and the University Hospital Wuerzburg, Germany) have been merged into one database.
Data include basic diagnostic data, clinical, biochemical and imaging outcomes, comorbidities
and medication use.
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For the purpose of the current study, all adult patients (age18 years) with a definite FD
diagnosis according to previously developed criteria [7], who were treatment naïve and were
subsequently treated with either agalsidase alfa or agalsidase beta for at least 9 months, were
included in this study. Baseline was defined as start of ERT; follow-up ended at discontinua-
tion of ERT, death or the last recorded visit. Switch to the other ERT type (agalsidase alfa or
agalsidase beta) was allowed. Concomitant treatment with an angiotensin-converting-enzyme
inhibitor (ACEi), angiotensin II receptor blocker (ARB), antiplatelet therapy and/or antihyper-
tensive therapy was administered according to guidelines prevalent at the time.
Phenotype
Patients were categorized as classical or non-classical on the basis of enzyme activity and the
presence or absence of characteristic FD symptoms (Fabry neuropathic pain, clustered angio-
keratoma and/or cornea verticillata) [6]. A detailed description of the classification method
has been published before and can be found in S1 File [5].
Clinical and biochemical outcomes and potential prognostic parameters
Clinical events. Clinical events were defined as follows:
• Renal events: CKD (Chronic Kidney Disease) stage G5 (estimated glomerular filtration rate
(eGFR) <15ml/min/1.73m2), renal transplantation or dialysis
• Cardiac events: atrial fibrillation, admission for any rhythm disturbance, admission for
congestive heart failure, implantation of an implantable cardiac defibrillator (ICD) or pace-
maker (PM), myocardial infarction, coronary artery bypass graft surgery or a percutaneous
transluminal angioplasty intervention
• Cerebral events: stroke or transient ischemic attack (TIA) diagnosed by a neurologist
• Death
Renal function. Renal function was evaluated by the estimated glomerular filtration rate
(eGFR) and the amount of protein excretion in urine. The eGFR was calculated using the
CKD-EPI formula [22]. The eGFR of patients who had received a renal transplant or were
undergoing dialysis was set at 10 ml/min/1.73m2.
Albuminuria and proteinuria excretion was categorization was adapted from the Kidney
Disease Improving Global Outcomes (KDIGO) guidelines [22]. Proteinuria was defined as
albumin excretion rate (AER) >300 mg/24 hours, protein excretion rate (PER)>500 mg/24
hours, albumin to creatinine ratio (ACR) >30 mg/mmol and/or protein to creatinine ratio
(PCR) >50 mg/mmol. Severe proteinuria was defined as: AER >600 mg/24 hours, PER >1000
mg/24 hours, AER >60 mg/mmol and/or PCR >100 mg/mmol.
Cardiac involvement. Cardiac involvement was assessed by echocardiography and MRI.
Left ventricular mass index (LVMI) measured by echocardiography was calculated using the
Devereux formula and was corrected for height (m2.7) [23]. The upper reference limit for men
and women is respectively 48 and 44 gram/m2.7 [23]. The upper reference limit of the relative
wall thickness (RWT) was defined as>0.42 [23]. Left ventricular mass not including papillary
muscles measured by cardiac MRI (LVMmri) was corrected for body surface area using the
Dubois formula. The upper reference limit, adjusted for not including papillary muscles (9%
on average), for men and women was estimated at respectively 78 and 74 gram/m2 [24–26]. In
addition, the presence of late gadolinium enhancement (LGE) on cardiac MRI was assessed as
marker of fibrosis.
Prognostic factors in Fabry disease
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Biochemistry. Biochemical analyses were performed at the Academic Medical Center
(AMC). Plasma lysoGb3 was analyzed using a previously described method (samples from
before August 2015 from the AMC), an alternative internal standard was used for all samples
from the Royal Free Hospital and the University Clinic Wuerzburg and samples after August
2015 from the AMC) [27, 28]. Plasma lysoGb3 levels determined using both internal standards
correlated very well [5].
Other variables. The presence of white matter lesions (WML) at baseline was assessed by
cerebral MRI. In addition, the use of ARB/ACE-inhibitors and the following cardiovascular
risk factors at baseline were included: hypertension, smoking, diabetes, body mass index
(BMI), high density lipoprotein cholesterol, low density lipoprotein cholesterol, total choles-
terol and triglycerides.
Methods
Clinical and biochemical outcomes during ERT were defined as the clinical event rate, decline
in eGFR, change in LVMI or LVMmri and change in lysoGb3 concentration. For these out-
comes, the following were evaluated as potential prognostic variables: age at start of ERT, sex,
phenotype, a history of one or more clinical events before baseline, baseline eGFR, proteinuria,
baseline cardiac measurements (including LVMI and LVMmri), baseline lysoGb3, the use of
ARB/ACE-inhibitors, and the previously detailed cardiovascular risk factors.
Statistical analysis
R (version 3.3.1) was used for statistical analysis. Data are presented as mean ± standard devia-
tion (SD) or median and range where appropriate.
A Cox proportional hazard model was used to study the influence of potential prognostic
factors on the event rate, defined as first renal, cardiac or cerebral event, or death. First, the
effect of age at start of ERT, sex and phenotype was modeled in a multivariate analysis. Because
of the expected strong effects of these variables, the other potential prognostic factors (i.e.
baseline disease parameters, use of ARB/ACE-inhibitors and cardiovascular risk factors) were
tested one by one in a cox regression model adjusted for age, sex and phenotype. Finally, a
multivariate model was built with age, sex, phenotype, baseline eGFR, baseline LVMI and a
history of one or more events before ERT as covariates. The proportional hazard assumption
was visually tested by using Schoenfeld residuals.
Mixed effect models (package: nlme) were used to analyze the influence of potential prog-
nostic factors on the change of eGFR, LVMI, LVMmri and lysoGb3 over time. Both LVM,
LMVmri and lysoGb3 values showed a decrease in the first year followed by generally stable
outcomes in the following years. In order to account for this non-linear relation, the change
from baseline was used in the mixed effect models. Similar to the Cox proportional hazard
models on the clinical event rate, we started with a multivariate model to study the effect of
age, sex and phenotype. This was followed by analyses of the influence of the other potential
prognostic factors. Per prognostic factor, covariates were selected in a combined expert judge-
ment and stepwise manner, and the Akaike Information Criterion (AIC) was used to evaluate
the goodness of fit. Consequently, stratification by age, sex, and phenotype was only applied if
addition of one or more of these variables resulted in a better model (for details see S2 File). In
addition, the ΔLVM analyses were stratified for the presence or absence of LVH at baseline,
and the eGFR analyses were stratified for low or high eGFR at baseline (eGFR <60 and60
ml/min/1.73m2, respectively). Mixed effect model assumptions were visually tested by diag-
nostic plots. Variance inflation factor (VIF) was used to explore potential multicollinearity. P-
Prognostic factors in Fabry disease
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values<0.05 were considered statistically significant. Results were reported in accordance to
the STROBE guidelines [29].
Ethics statement
According to Dutch law, and after review of the AMC ethics committee, no approval of the
study protocol was needed because of the observational nature of the study. All data were
obtained from medical records. Patient records were anonymized and de-identified prior to
analysis. All patients have provided consent for the use of their medical data and samples in
accordance with local ethics requirements.
Results
ERT with either agalsidase alfa or beta was started in 337 patients. Of these, 44 patients were
excluded because follow up was too short (<9 months) or ERT was started before the age of
18, resulting in a total of 293 patients included in this study (Table 1). The cohort consisted of
163 (55.6%) men and 130 (44.4%) women, median age at ERT initiation was 45.5 years (range:
18–79), and the median follow up time was 6.8 years (range: 0.8–15.4). One hundred patients
changed in dose or preparation during follow up. In 78 patients the dose of agalsidase beta was
temporarily lowered or switched to agalsidase alfa, mainly as a result of shortage of agalsidase
beta. For the purpose of this study, outcomes of treatment with agalsidase alfa and beta were
combined. Longitudinal data on outcomes were available for 263, 234, 73 and 163 patients, for
respectively eGFR, LVMI, LVMmri and lysoGb3.
Clinical events
Clinical events occurred in 102 (34.8%) patients while on ERT (Fig 1), resulting in 0.66 events
per 10 patient years at risk. During this period, 67 patients had a cardiac and 18 a renal event;
30 patients developed a stroke or TIA and 17 patients died. The distribution of the first events
was: cardiac in 53, renal in 16, stroke or TIA in 24 and death in 9 patients. For detailed infor-
mation on the distribution and number of events per phenotype see S1 Table.
Effect of age, sex and phenotype on clinical and biochemical outcomes
The first analysis showed a strong association between age, sex and phenotype and the
development of clinical events (Table 2). The risk to develop a clinical complication doubled
with every 10 years increase in age at start of ERT. Compared to non-classical FD women,
classical FD men had a 4.6 times higher risk to develop an event. They also had a more
severe decline in renal function compared to the other subgroups while, in contrast, the
cardiac mass and lysoGb3 concentration improved more prominently in in men with classi-
cal FD.
The effect of other prognostic factors on clinical and biochemical
outcomes
Table 3 shows the hazard ratios (HRs) of the additional potential prognostic variables on the
clinical event rate, adjusted for age at start of ERT, sex and phenotype. In the following para-
graphs, the prognostic variables and the magnitude of their effect on the clinical event rate,
renal function and cardiac mass are discussed. None of the variables predicted the decrease in
lysoGb3. Individual lysoGb3 concentrations and the course upon ERT are shown in Fig 2 and
S1 Fig.
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Events before ERT. A history of one or more events before ERT was significantly associ-
ated with the development of new clinical events (HR: 2.37, p<0.001), cardiac events (HR:
2.56, p = 0.005) and cerebral events (HR: 2.36, p = 0.02). In patients who had suffered a cere-
bral event before ERT initiation, the risk of developing another cerebral event was tripled (HR:
3.08, p = 0.007). Similarly, the risk of developing a cardiac event was increased in patients with
a history of a cardiac event before ERT (HR: 1.97, p = 0.04).
Table 1. Baseline characteristics.
All Classical men Non-classical men Classical women Non-classical women missing
Patients 293 121 42 82 48 0
Age at start ERT (years) 46 (18–79) 38 (18–63) 59 (18–76) 48 (20–75) 51 (19–79) 0
Median dose (mg/kg/EOW) 0.2 (0.2–1.0) 0.4 (0.2–1.0) 0.2 (0.2–1.0) 0.2 (0.2–1.0) 0.2 (0.2–1.0) 0
Agalsidase beta as first ERT 115/293 (39%) 67/121 (55%) 6/42 (14%) 29/82 (35%) 13/48 (27%) 0
Follow up (years) 6.3 (0.8–15.4) 7.2 (0.8–15.4) 4.0 (0.9–14.3) 7.0 (0.8–13.6) 5.9 (1.0–13.0) 0
ERT discontinued 23/293 (8%) 12/121 (10%) 3/42 (7%) 5/82 (6%) 3 (6.2%) 0
Event(s) before ERT start 77/293 (26%) 30/121 (25%) 18/42 (43%) 19/82 (23%) 10/48 (21%) 0
Cardiac event(s) before ERT start 40/293 (14%) 11/121 (9%) 17/42 (40%) 6/82 (7%) 6/48 (13%) 0
Cerebral event(s) before ERT start 41/293 (14%) 18/121 (15%) 6/42 (14%) 12/82 (15%) 5/48 (11%) 0
Renal event(s) before ERT start 16/293 (6%) 13/121 (11%) 2/42 (5%) 1/82 (1%) 0/48 (0%) 0
eGFR (ml/min/1.73m2) 91 (5–140) 102 (5–139) 79 (5–136) 93 (5–140) 87 (32–126) 14 (5%)
eGFR <60 ml/min/1.73m2 54/279 (19%) 29/113 (26%) 11/42 (26%) 5/77 (6%) 9/47 (19%) 14 (5%)
Proteinuria (CKD A3) 62/233 (26.6%) 33/95 (35%) 9/27 (33%) 14/71 (20%) 6/40 (15%) 60 (20%)
IVSd (mm) 12 (6–24) 12 (6–24) 14 (8–24) 11 (7–24) 11 (6–19) 46 (16%)
RWT 0.49 (0.25–2.50) 0.48 (0.26–2.50) 0.49 (0.25–0.96) 0.50 (0.25–0.88) 0.50 (0.29–1.03) 57 (19%)
RWT >0.42 167/236 (71%) 67/96 (73%) 23/30 (77%) 47/71 (66%) 30/43 (70%) 57 (19%)
LVMI (gram/m2.7) 51 (16–149) 52 (24–149) 59 (16–105) 46 (25–120) 49 (16–96) 57 (19%)
LVH 137/236 (58%) 53/96 (58%) 21/30 (70%) 37/71 (52%) 26/43 (60%) 57 (19%)
Concentric remodeling 44/236 (19%) 18/96 (20%) 4/30 (13%) 16/71 (23%) 6/43 (14%) 57 (19%)
Concentric hypertrophy 123/236 (52%) 49/96 (53%) 19/30 (63%) 31/71 (44%) 24/43 (56%) 57 (19%)
LVMmri (gram/m2) 87 (39–184) 94 (43–184) 120 (75–132) 74 (39–137) 84 (49–163) 212 (72%)
LGE 34/76 (45%) 17/43 (40%) 1/2 (50%) 10/22 (45%) 6/9 (67%) 217 (74%)
Presence of WML 75/122 (61%) 26/43 (60.5%) 7/14 (50%) 30/41 (73%) 12/24 (50%) 171 (58%)
LysoGb3 (nmol/l) 15.5 (0.7–178) 110 (38–178) 7.7 (5.6–10.6) 10.1 (2.7–23.5) 6.2 (0.7–20.0) 108 (37%)
Use of ARB/ACE-inhibitors 86/293 (29%) 24/121 (20%) 18/42 (43%) 23 (28%) 21/48 (44%) 0
Hypertension 99/279 (35%) 33/116 (28%) 18/36 (50%) 25/79 (32%) 23/48 (48%) 14 (5%)
Smoking 68/263 (25%) 33/106 (31%) 10/38 (26%) 16/73 (22%) 9/46 (20%) 30 (10%)
Diabetes 12/214 (6%) 0/70 (0%) 5/39 (13%) 2/72 (3%) 5/38 (13%) 79 (27%)
BMI (kg/m2) 24 (16–42) 22 (16–31) 27 (20–41) 25 (18–38) 25 (18–42) 19 (6%)
Dyslipidemia 47/211 (22%) 4/71 (6%) 17/35 (49%) 10/65 (15%) 16/40 (40%) 82 (28%)
HDL cholesterol (mmol/l) 1.5 (0.7–2.9) 1.4 (0.8–2.6) 1.3 (0.7–2.3) 1.6 (0.8–2.8) 1.6 (0.7–2.9) 90 (31%)
LDL cholesterol (mmol/l) 2.6 (0.5–5.3) 2.4 (1.1–4.8) 2.8 (0.7–4.8) 2.7 (1.4–5.0) 2.8 (0.5–5.3) 53 (18%)
Total cholesterol (mmol/l) 4.8 (2.4–7.4) 4.3 (2.4–6.7) 5.0 (2.4–7.4) 5.0 (3.3–8.1) 5.5 (3.5–7.4) 47 (16%)
Triglycerides (mmol/l) 1.2 (0.4–5.9) 1.0 (0.4–3.4) 1.6 (0.8–5.6) 1.1 (0.4–3.0) 1.4 (0.5–5.9) 50 (17%)
Continuous variables are presented as median (range) and discrete variables as proportions (percentages). ERT: enzyme replacement therapy, eGFR:
estimated glomerular filtration rate, CKD: chronic kidney disease, IVSd: interventricular septum in diastole, RWT: relative wall thickness, LVMI: left
ventricular mass index measured by echocardiography adjusted for height2.7, LVH: left ventricular hypertrophy, concentric remodeling was defined as a
RWT >0.42 in the absence of LVH, concentric hypertrophy was defined as a RWT >0.42 and LVH, LVMmri: left ventricular mass measured by MRI adjusted
for BSA, LGE: late gadolinium enhancement, WML: white matter lesions, ARB: angiotensin receptor blocker, ACE-inhibitors: angiotensin-converting-
enzyme inhibitors, BMI: body mass index, HDL: high density lipoprotein, LDL: low density lipoprotein.
https://doi.org/10.1371/journal.pone.0182379.t001
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Renal function. With every 10 ml/min/1.73m2 lower eGFR at baseline, there was a 19%
increased risk to develop a clinical event (HR: 1.19, p<0.001). This influence of renal function
is further shown in Fig 3, which depicts increasing HRs with lower eGFR at start of ERT.
Twelve patients experienced a first renal event while on ERT, who had a median eGFR at base-
line of 20 ml/min/1.73m2. The majority of these patients were classical men (n = 10); the other
two patients were non-classical men, while none of the women had a renal event during follow
up. A lower eGFR at baseline was associated with an increased risk of developing a first renal
event (HRper -10ml/min/1.73m
2: 5.57, p = 0.02). The influence of eGFR was further shown by a
Fig 1. Event free survival all patients treated with ERT combined. Shaded areas represent the 95% CI.
Crosses indicate censoring.
https://doi.org/10.1371/journal.pone.0182379.g001
Table 2. Effect of age, sex and phenotype on clinical and biochemical outcomes.
Clinical events (HR) eGFR slope LVMI reduction during first year LysoGb3 reduction during first year
Age (per 10 years) 1.96†† 0.0 -1.6 0.7
(1.61-2.38) (-0.3 – 0.2) (-4.1 – 1.0) (-1.7 – 3.1)
Classical men 4.61††† -2.7††† -5.9†† -74.7†††
(2.23 – 9.53) (-3.1 – -2.3) (-9.6 – -2.2) (-78.4 – -63.6)
Non-classical men 1.78 -1.8††† -0.8 -5.0
(0.84 – 3.74) (-2.5 – -1.1) (-8.5 – 6.9) (-14.1 – 4.1)
Classical women 1.14 -1.3††† -6.3† -3.7
(0.55 – 2.36) (-1.7 – -0.8) (-11.3 – -1.3) (-9.2 – 1.9)
Non-classical women 1.00§ -1.4††† -0.4 -3.1
(-2.0 – -0.8) (-7.0 – 6.1) (-10.6 – 4.5)
The models included age, sex and phenotype and the interaction between sex and phenotype as covariates. For the LVMI analysis only the results for the
LVH group are shown. Units eGFR slope: ml/min/1.73m2/year, LVMI reduction during first year: gram/m2.7, lysoGb3 reduction during first year: nmol/l.
†p < 0.05;
††p < 0.01;
†††p<0.001.
§ reference category
https://doi.org/10.1371/journal.pone.0182379.t002
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stronger decline in eGFR in classical men with a baseline eGFR below 60 ml/min/1.73m2 com-
pared to those with an eGFR above 60 (Table 4 and S2 Fig). There was no relation between the
eGFR at baseline, the decrease in LVMI, or for the separate analysis of cardiac and cerebral
events.
Proteinuria. Proteinuria (PER>0.5 gram/day or equivalent) at baseline did not result in
a higher clinical event rate but in patients with proteinuria an additional decline in eGFR of
-0.9 ml/min/1.73m2 per year (p = 0.005) was found. This was even more prominent in patients
Table 3. Influence of potential prognostic variables on the clinical event rate, adjusted for age, sex
and phenotype.
HR 95% CI N
Event(s) before ERT start 2.37††† 1.47 – 3.85 293
Cardiac event(s) before ERT start 1.83 0.99 – 3.37 293
Cerebral event(s) before ERT start 1.54 0.86 – 2.77 293
Renal event(s) before ERT start 1.29††† 1.81 – 7.21 293
eGFR (per -10 ml/min/1.73m2) 1.19††† 1.11 – 1.27 279
eGFR <60 ml/min/1.73m2 3.58††† 2.12 – 6.05 279
Proteinuria (CKD A3) 1.40 0.84 – 2.33 233
IVSd (per mm) 1.05 0.97 – 1.14 247
RWT (per 0.1) 1.12† 1.02 – 1.24 236
RWT >0.42 1.14 0.60 – 2.17 236
LVMI (per 10 gram/m2.7) 1.25†† 1.08 – 1.45 236
LVH 1.61 0.89 – 2.88 236
LVMmri (per 10 gram/m2) 1.13 0.91 – 1.41 81
LGE 1.09 0.37 – 2.99 76
WML 1.02 0.40 – 2.57 122
LysoGb3 (per 10 nmol/l) 1.06 0.95 – 1.19 185
Use of ARB/ACE-inhibitors 1.35 0.82 – 2.20 293
Hypertension 1.87†† 1.18 – 2.97 279
Smoking 1.14 0.65 – 2.01 263
Diabetes 1.07 0.27 – 3.23 214
BMI (per kg/m2) 1.04 0.98 – 1.11 274
HDL cholesterol (per 1 mmol/l) 0.58 0.77 – 1.40 203
LDL cholesterol (per 1 mmol/l) 1.04 0.29 – 1.18 240
Total cholesterol (per 1 mmol/l) 0.96 0.73 – 1.27 246
Triglycerides (per 1 mmol/l) 1.38† 1.06 – 1.81 243
Cox regression analysis on the clinical event rate, adjusted for age, sex and phenotype. The hazard ratio
(HR) for each individual prognostic factors was calculated one by one.
N: number of patients included in the analysis, ERT: enzyme replacement therapy, eGFR: estimated
glomerular filtration rate, CKD: chronic kidney disease, IVSd: interventricular septum in diastole, RWT:
relative wall thickness, LVMI: left ventricular mass index measured by echocardiography adjusted for
height2.7, LVH: left ventricular hypertrophy, concentric remodeling was defined as a RWT >0.42 in the
absence of LVH, concentric hypertrophy was defined as a RWT >0.42 and LVH, LVMmri: left ventricular
mass measured by MRI adjusted for BSA, LGE: late gadolinium enhancement, WML: white matter lesions,
ARB: angiotensin receptor blocker, ACE-inhibitors: angiotensin-converting-enzyme inhibitors, BMI: body
mass index, HDL: high density lipoprotein, LDL: low density lipoprotein.
†p < 0.05;
††p < 0.01;
†††p<0.001.
https://doi.org/10.1371/journal.pone.0182379.t003
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with severe proteinuria (PER>1 gram/day or equivalent) (β: -1.5 ml/min/73m2/year,
p<0.001). When considering classical men only, the additional decline in eGFR slope was -1.4
ml/min/73m2/year (p = 0.02) and -2.7 ml/min/73m2/year (p<0.001) in patients with>0.5
gram/day and>1.0 gram/day proteinuria, respectively.
LVMI and RWT. Per 10 grams increase in LVMI at baseline, there was a 25% higher risk
of developing an event (HR: 1.25, p = 0.003). The association between LVMI and risk for car-
diac events (HR: 1.13, 95% CI: 0.98–1.30, p = 0.09) was similar to that of cardiac and cerebral
events combined (HR: 1.18, 95% CI: 0.98–1.44, p = 0.09). An increased RWT at the start of
ERT resulted in an increased clinical even rate (HRper 0.1: 1.12, p = 0.02).
In patients without LVH there was no change in LVMI during the first year (β: 1.5 gram/
m2.7, p = 0.19), while in patients with LVH at baseline a moderate decrease in LVMI was
observed (β: -5.4 gram/m2.7, p<0.001). This initial decrease in LVMI highly depended on the
Fig 2. LysoGb3 in classical men. LysoGb3 concentrations in nmol/l per individual patient.
https://doi.org/10.1371/journal.pone.0182379.g002
Fig 3. Hazard ratios for different cut off points of eGFR at baseline. Hazard ratios compared to a baseline
eGFR of >90 ml/min/1.73m2, adjusted for age, sex and phenotype.
https://doi.org/10.1371/journal.pone.0182379.g003
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severity of baseline LVH: patients with a LVMI below 70 gram/m2.7 showed no significant
change (β: -1.9 gram/m2.7, p = 0.19), whereas patients with a LVMI above 70 gram/m2.7
showed a 13.6 gram/m2.7 decrease (p<0.001) over the first year (S3 Fig). Over the following
years there was no change in LVMI in both the LVH and non-LVH group (β: 0.2 gram/m2.7/
year, p = 0.16).
LVMmri and fibrosis. Data on LVMmri and fibrosis (LGE) at baseline were available for
81 and 76 patients, respectively. Neither LVMmri nor fibrosis was associated with the clinical
event rate, but both were predictive for the change in LVMmri during treatment: similar to the
echocardiography results, an increased LVMmri at baseline resulted in a 4.7 gram/m2 decrease
(p = 0.008) in LVMmri during the first year of ERT, while LVMmri remained stable if it was
normal at start of ERT (β = 0.9 gram/m2, p = 0.69). After the first year an annual increase was
observed in both groups (β: 1.8 gram/m2/year, p<0.001). The strongest increase (β: 3.4 gram/
m2/year, p<0.001) was found in patients with LVH and fibrosis while in patients with LVH
but without fibrosis a trend towards a yearly increase (β: 1.4 gram/m2/year, p = 0.052) was
observed. In 18/39 (46%) of the patients without fibrosis at start of ERT, fibrosis developed
after a median period of 8.2 years (range 1.7–12.1). Patients who developed fibrosis had a
higher LVMmri at baseline compared to those who did not develop fibrosis (median LVMmri:
80 vs 101 gram/m2, p<0.001). Sex and phenotype were equally distributed among both
groups.
Use of ARB/ACE-inhibitors. ARB/ACE-inhibitors were prescribed in 86/293 (29%)
patients at baseline, of whom 32/86 (37%) had proteinuria. Considering the whole cohort, 62
patients had proteinuria at baseline of whom 32 (52%) received an ARB/ACE-inhibitor at
baseline, which increased to 59 (95%) during follow-up. The use of ARB/ACE-inhibitors was
not related to the annualized change in renal function, change in LVMI or event rate.
Cardiovascular risk factors. Triglyceride levels (HRper mmol/l: 1.38, p = 0.02) and hyper-
tension (HR: 1.12, p = 0.007) were both associated with an increased clinical event rate. Other
cardiovascular risk factors did not influence the risk of a clinical event (Table 3).
LysoGb3. Neither the lysoGb3 concentration at baseline (HRper 10 nmol/l 1.06, p = 0.30),
the lysoGb3 concentration during treatment (HRper 10 nmol/l: 0.93, p = 0.45), the absolute
decrease of lysoGb3 (HRper 10 nmol/l: 1.07, p = 0.24), nor the relative decrease of lysoGb3 (HR:
1.00, p = 0.13) predicted the risk of events.
Multivariate analysis. The multivariate analysis with age, sex, phenotype, baseline eGFR,
baseline LVMI and a history of one or more events before ERT as covariates showed that a
lower eGFR independently resulted in an increased clinical event rate. In addition, there was a
trend towards an increased event rate with higher LVMI (Table 5). A model with eGFR as a
Table 4. Annualized change in eGFR stratified for eGFR at baseline.
eGRF60 eGRF <60
Slope 95% CI Slope 95% CI Δ 95% CI
Classical men -2.5††† -2.9 – -2.1 -4.5††† -5.6 – -3.3 -2.0††† -3.2 – -0.8
Non-classical men -1.6††† -2.4 – -0.8 -3.3††† -5.1 – -1.5 -1.7 -3.6 – 0.2
Classical women -1.3††† -1.7 – -0.8 -0.3 -2.6 – 2.0 1.0 -1.4 – 3.3
Non-classical women -1.4††† -2.1 – -0.8 -1.5† -2.8 – -0.2 -0.1 -1.5 – 1.4
Mixed effect model on annualized change in eGFR in ml/min/1.73m2/year, adjusted for sex and phenotype. Number of patients included in the analysis:
263.
†p < 0.05;
†††p<0.001.
https://doi.org/10.1371/journal.pone.0182379.t004
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dichotomous variable (eGFR<60 and60 ml/min/1.73m2) revealed a significant association
with eGFR and LVMI, and a trend for events before start of ERT (S2 Table). LVMI and clinical
events before ERT were significantly associated with an increased event rate when excluding
renal events from the analysis (S3 Table). Hypertension and triglyceride were not independent
predictors of event rate (HRhypertension: 0.80, p = 0.52; HRtriglyceride: 1.20, p = 0.30).
Discussion
During treatment of patients with FD with enzyme replacement therapy, age, sex and pheno-
type are strong predictors of the risk to develop clinically important events and of decline in
renal function. This is no surprise as these groups have a different rate of disease progression
as described earlier [5]. However, it is of interest to see how important these differences are:
men with classical FD have for example a five times higher risk for events compared to women
with non-classical FD, and with every 10 years increase in age, the risk of events doubles.
To be able to determine the influence of other biochemical and clinical parameters we
performed an analysis adjusted for age, sex and phenotype. The strongest association were
observed for the presence of clinical event before the initiation of ERT and eGFR. Renal func-
tion was particularly associated with an increased risk of renal events. These results are in line
with the findings of Banikazemi et al, who showed less treatment efficacy in patients with an
eGFR below 55 ml/min/1.73m2 [15]. Interestingly, the event rate in the present study is com-
parable to the event rate of CFDI 1a cohort but lower compared to the estimated event rate in
the Banikazemi trial, probably due to different inclusion criteria [15, 30]. Recently, both the
presence of moderately impaired renal function and LVH were established as risk factors for
an increased event rate in a univariate analysis [14]. In the present study, a multivariate analy-
sis showed that eGFR, and to a lesser extent cardiac mass, were independent risk factors for an
increased event rate. Besides event rate, it is shown that low eGFR at baseline is associated with
a stronger decline in eGFR during treatment, especially in men with classical FD, in line with
previous reports [31, 32]. However, also in classical men with a preserved kidney function at
baseline a considerable decline in renal function was observed. In men with non-classical dis-
ease and women the decline in eGFR in was slower, depended less on the kidney function at
treatment start and resembles the natural course of FD [5, 33]. In addition, baseline protein-
uria is a strong predictor of the decline in eGFR in treated patients which is, again, most evi-
dent in classical men [13, 32, 34, 35].
Consistent with earlier observations we found that the cardiac mass decreases over the first
year of ERT and remains relatively stable afterwards [36]. In the present analysis, cardiac mass
Table 5. Multivariate analysis.
HR 95% CI
eGFR (per -10 ml/min/1.73m2) 1.12†† 1.03–1.22
LVMI (per 10 gram/m2.7) 1.16 0.99–1.36
Event(s) before ERT 1.45 0.85–2.53
Cox regression analysis on the clinical event rate, adjusted for age, sex and phenotype. The hazard ratios
(HR) of eGFR, LVMI and events before ERT on the clinical event rate were calculated in a multivariate
model. Number of patients included in the analysis: 233. eGFR: estimated glomerular filtration rate, LVMI:
left ventricular mass index measured by echocardiography adjusted for height2.7, ERT: enzyme replacement
therapy.
††p < 0.01;
https://doi.org/10.1371/journal.pone.0182379.t005
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at baseline predicted the reduction of LVMI after initiation of ERT: a higher cardiac mass was
associated with a larger reduction in LVMI. Thus, unlike eGFR, more severe disease i.e. more
extensive hypertrophy, is associated with a better response. This suggests that cardiac disease is
more reversible and is more responsive to ERT than kidney disease. However, irreversible
damage to the heart as evidenced by the presence of fibrosis on MRI, is associated with worse
outcome. Weidemann and colleagues previously reported less improvement in strain rate and
cardiac mass in patients with fibrotic changes in the heart [37]. Interestingly, in our study the
initial decline of cardiac mass was independent of the presence of cardiac fibrosis, although
the increase in cardiac mass over the following years was stronger in those with fibrosis. The
presence of fibrosis in the heart is of clinical importance: not only does it indicate relative resis-
tance to effect of treatment [38], it is also strongly related to malignant ventricular arrhythmias
[37, 39], putting patients at risk of sudden cardiac death. In general, early start of ERT has
been advocated as a possibility to increase the beneficial effect of ERT and prevent the forma-
tion of irreversible organ damage such as cardiac fibrosis or further decline in kidney function
[16, 31, 34]. Indeed, at young age, i.e. before 35 years of age, cardiac fibrosis is very uncommon
in FD [5, 40]. Consequently it has been hypothesized that initiation of ERT before the occur-
rence of fibrosis might improve the treatment response and hopefully prevent the development
of fibrosis [37]. However, during follow-up almost half of the patients without cardiac fibrosis
at baseline developed cardiac fibrosis.
WML have usually been reported, with few exceptions, as being resistant to ERT [41–43].
In the current study, evolution of WML over time was not studied. However, the presence of
WML at baseline did not predict the risk of developing cerebral events. A limitation of this
analysis is that the number of patients was relatively small and a bias may have been induced
by exclusion of patients with ICDs or pacemakers: indeed strokes and TIAs occurred in 30
patients of whom in only 10 MRIs at baseline were available.
ERT clearly has an effect on the most sensitive sphingolipid marker in FD, plasma lysoGb3
[44]. The most robust decrease in lysoGb3 is established in classical men, although all remain
elevated even after prolonged periods of time. As previously reported, antibody formation in
classical men may affect the biochemical response to therapy. We will evaluate this in a com-
parative study between agalsidase alfa and beta at their licensed dose. It could be expected that
less decline in lysoGb3 was associated with more events or decline in GFR, but this could not
be established. We hypothesize that the lack of association is explained by the fact that ERT is
almost invariably able to reduce storage, but only partially able to influence clinical outcomes
because of the presence of irreversible damage.
Investigations on general cardiovascular risk factors in FD are limited. Small alterations in
cholesterol in FD patients have been reported but a relationship with clinical outcomes has not
been established [45, 46]. In this study, triglyceride levels, but not cholesterol, were related to
an increased event rate when adjusting for age, sex and phenotype. However, samples were not
always drawn in a fasting state. Nevertheless, it may be of importance to explore whether lipid-
lowering therapy is useful. In addition, hypertension was associated with an increased event
rate. Elevated systolic blood pressure has previously been reported to be associated with pro-
gression of cardiac fibrosis in FD [38]. These findings together clearly emphasize the need for
strict control of blood pressure. Among the most used adjunctive treatments in FD are ARB/
ACE-inhibitors. They are frequently prescribed for treatment of proteinuria [22] but also for
hypertension or cardiac failure. No relation between the use of ARB/ACE-inhibitors and clini-
cal outcomes were established in the current study, which may have been due to the variety of
indications for use of the drugs. However, a previous study evaluating the effect of combined
treatment with an intensified ERT dose and ARB/ACE-inhibitors showed that reaching the
treatment goal of a PCR <50 mg/mmol resulted in preservation of the kidney function [34].
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Hence, it is paramount that FD patients should receive optimal adjunctive treatment, includ-
ing ARB/ACE-inhibitors [47].
In conclusion, age, sex and phenotype are the most important predictors for the long-term
outcome of ERT in FD. The potential benefit of ERT in patients with impaired renal function,
proteinuria and/or cardiac fibrosis seems to be limited. Specifically, the risk for events in
patients with severely impaired renal function remains high. Although disease progression is
also observed in those without extensive organ involvement, treatment before the occurrence
of irreversible organ damage might lead to more favorable outcomes. These results may further
fuel the discussion on the initiation and discontinuation of ERT in FD [19].
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